Real Money authors - Bruce Kamich

Bruce Kamich

Bruce Kamich is TheStreet's in-house technical analyst with a 43 year career with a number of bulge bracket firms like Morgan Stanley, Smith Barney Harris Upham, and Merrill Lynch. Along the way he accumulated knowledge about the fundamentals of the commodity markets, interest rates, equities and ETFs. 

In addition to writing for Kamich has been teaching technical analysis at Baruch College for the past twenty years.

Kamich was one of the earliest Chartered Market Technicians  or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works"  and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (
Email Bruce Kamich

Recent Articles By The Author

How Does Salesforce Look Ahead of Earnings and Inclusion in the DJIA?

Our latest analysis and trading strategy for the stock.

A Technical Look at the New Dow Jones Industrial Average

Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.

Best Buy Sees Post-Earnings Pullback -- So Should You Buy?

We believe BBY can still work higher after a brief falling on Tuesday.

International Flavors & Fragrances Needs to Prove It Can Rally

Traders should wait for price strength and expanded volume.

Fiserv Stock Is Not in the Clover

FISV could weaken further in the short-term.

Shares of Opko Health Are Still 'Testing Negative'

Opko's BioReference Labs has performed over 4.3 million Covid-19 tests thus far.

Charts of Palo Alto Networks Are Securely Bullish

A recent dip in the shares of the cybersecurity company could be an opportunity to buy on short-term weakness.

Pfizer Is Poised for an Upside Breakout: Here's Our Strategy

Let's check out the latest charts and indicators to plot a technical strategy.

Stay Patient With AbbVie

I would continue to hold ABBV, and here's why.

Sticking With Our Strategy on Crown Castle

There's a temptation to cut and run.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight